Details Basic Details Date Tuesday, August 27, 2019 Type Presentation Medical Product biosimilar filgrastim infliximab Materials Biosimilar Use in the United States: A Sentinel Analysis of Filgrastim and Infliximab Additional Information Information Host 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management Related Assessment(s) Abstracts of the 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Pennsylvania Convention Center, Philadelphia, PA, USA, August 24‐28, 2019 Investigation of Nonproprietary Name Suffix Use for Biologics and Biosimilars Understanding Utilization Patterns of Biologics and Biosimilars in the United States to Support Postmarketing Studies of Safety and Effectiveness Sentinel Drug Study: Neupogen (filgrastim), Remicade (infliximab), and Neulasta (pegfilgrastim) & Biosimilar Use Contributors Presenter(s) Sarah K. Dutcher, Efe Eworuke, Elnara Fazio-Eynullayeva, Elizabeth Dee, Michael D. Nguyen, Catherine A. Panozzo